Life expectancy in patients with metastatic renal cell carcinoma in the Russian Federation: results of the RENSUR3 multicenter registry study

Background. Overall survival (OS) data obtained in patients with metastatic renal cell carcinoma (mRCC) in real-world settings are rarely published. The objective of the RENSUR3 registry study was to collect information on the use of various therapeutic options for mRCC in real-world clinical practice and assess OS in a Russian population.

Methods. Patients were retrospectively identified at 8 cancer centres in different Russian regions and enrolled in the study if the diagnosis of mRCC had been made in the period from January 2015 to December 2016. Anonymous data were collected online, the registry contained demographic characteristics and treatment and outcome data.

Results. The study had 573 subjects included in the analysis. The average age of patients at mRCC diagnosis was 63.1 years; 14.5 % of them were aged > 75 years. 65.6 % of the subjects were men; 72% had received surgical treatment for the primary tumour; clear cell and non-clear cell carcinomas were detected in 84 % and 16 % of the patients, respectively.

Drug therapy was used in 307 patients (54%). The median duration of any line of therapy was 10 months (95% CI 7.6-12.4). The most frequent treatment option was interferon (administered 161 times as part of any line of therapy or at different stages of treatment). Targeted therapy was given to 160 patients (52.1%), 112 of whom received it as first-line therapy. 87 subjects (28.3%) received > 2 lines of therapy. The 3-year OS rate was 21%, and the median OS was 12 months (95% CI 11.1-12.9). The median OS in the therapy and no therapy groups was 15.1 months and 6.9 months, respectively (Р<0.0001). The median life expectancy in patients receiving second-line therapy (median 18.4 months) was significantly higher than in patients treated with first-line therapy only (10.9 months, Р<0.001).

Conclusions: The OS results of the RENSUR3 study are unsatisfactory, which apparently can be explained by the fact that drug therapy was used in only half the patients, the infrequent use of targeted drugs, and the rare administration of targeted therapy for second and subsequent lines of therapy in patients with progressive disease. Introduction of the latest drug therapy options, including checkpoint inhibitors, will help improve patients» life expectancy.

1. Kaprin A, Starinskiy V, Petrova G. Malignant tumors in Russia in 2015 (morbidity and mortality). Moscow. 2017. p.250. ISBN 978-5-85502-227-8

2. Tsimafeyeu I, Aksel E. Renal Cell Carcinoma in the Russian Federation in 2008. Malign Tumours 1 (2010): 1-4.

3. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer, version 1.2015.

4. Tsimafeyeu I, Zart JS, Chung B. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-a. BJU International 112 (1), 32-38.

5. НосовД.А.,ВоробьевН.А., ГладковО.А., ссоавт. Практические рекомендации по лекарственному лечению почечноклеточного рака. Злокачественные опухоли. 2015. — № 4, спецвыпуск. — C.281-285. doi: 10/18027/2224-5057-2015-4s-281-285

6. Минаков С.Н., Левина Ю.В., Простов М.Ю. Популяционный раковый регистр. Функциональные возможности, задачи и существующие проблемы. Злокачественные опухоли. 2019;9 (1):6—9. doi: 10.18027/2224-5057-2019-9-1-6-9

7. Состояние онкологической помощи населению России в 2017 году (под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой) М.: МНИОИ им. П.А. Герцена филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018.-илл. 236 с. ISBN 978-5-85502-237-7

8. Ramaswamy A, Joshi A, Noronha V, et al. Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma-Results From a Tertiary Cancer Center in India. ClinGenitourin Cancer. 2017 Jun;15 (3):e345-e355.

9. Coelho RC, Reinert T, Campos F, et al. Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience. IntBraz J Urol. 2016 Jul-Aug;42 (4):694-703.

10. Nurgaliev N, Kaidarova D, Shatkovskaya O, et al. Real-world outcomes in patients with metastatic renal cell carcinoma in Kazakhstan. Presented at the Fourteenth Annual European International Kidney Cancer Symposium, 2019.

11. Kim JK, Kim SH, Song MK, et al. Application of the International Metastatic Renal Cell Carcinoma Database Consortium and Memorial Sloan Kettering Cancer Center Risk Models in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multi-Institutional Retrospective Study Using the Korean Metastatic Renal Cell Carcinoma Registry. Cancer Res Treat.2018 Sep 7. doi: 10.4143/crt.2018.421. [Epub ahead of print].

12. Poprach A, Lakomy R, Bortlicek Z, et al. Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice. Drugs Aging. 2016 Sep;33 (9):655-63.

13. Bergerot PG, Bergerot CD, Dizman N, et al. Assessment of Treatment Patterns for Metastatic Renal Cell Carcinoma in Brazil. J Glob Oncol. 2018 Sep;4:1-8.

14. Boegemann M, Hubbe M, Thomaidou D, et al. Sunitinib Treatment Modification in First-Line Metastatic Renal Cell Carcinoma: Analysis of the STAR-TOR Registry. Anticancer Res. 2018 Nov;38 (11):6413-6422.

15. Finek J, Demlova R, Kopeckova K, et al. Treatment sequences in metastatic renal cell carcinoma: Efficacy results from the Czech registry (RENIS). Annals of Oncology, Volume 29, Issue suppl_8, October 2018, mdy283.101, https://doi.org/10.1093/annonc/mdy283.101

16. Rini BI, de La Motte Rouge T, Harzstark AL, et al. Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib. ClinGenitourin Cancer. 2013 Jun;11 (2):107-14.

17. Tsimafeyeu I, Borisov P, Abdelgafur A, et al. Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx. Target Oncol. 2019 Feb;14 (1):33—38.

18. McDermott DF, Motzer RJ, Atkins MB, et al. Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies. J ClinOncol 34, 2016 (suppl; abstr 4507).

19. Albiges L, Negrier S, Dalban C, et al. Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Final analysis from the NIVOREN GETUG AFU 26 study. J ClinOncol 37, 2019 (suppl 7S; abstr 542).

20. De Giorgi U, Carteni G, Giannarelli D, et al. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. BJU Int. 2019 Jan;123 (1):98-105.

21. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 5;373 (19):1803-13.

22. Sharma P. et al. 16th International Kidney Cancer Symposium; November 3-4, 2017; Miami, FL, USA.

23. Rao A, Wiggins C, Lauer RC. Survival outcomes for advanced kidney cancer patients in the era of targeted therapies. Ann Transl Med. 2018 May;6 (9):165.

24. Tsimafeyeu I, Zolotareva T, Varlamov S, et al. Five-year overall survival among patients with metastatic renal cell carcinoma: Results of Russian population-based study RENSUR5. J ClinOncol 35, 2017 (suppl 5S; abstr 20).

25. Tsimafeyeu I, Zolotareva T, Varlamov S, et al. Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry. ClinGenitourinCancer. 2017 Dec;15 (6):e1069-e1072.

26. Li P, Jahnke J, Pettit AR, Wong YN, Doshi JA. Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare Patients With Metastatic Renal Cell Carcinoma. JAMA Netw Open. 2019 Jun 5;2 (6):e195806.

27. Shteynshlyuger A. Many Elderly Patients With Stage IV Metastatic Renal Cell Carcinoma May Benefit From More-Aggressive Treatment. JAMA Netw Open. 2019 Jun 5;2 (6):e195815.